Wall Street Zen Upgrades TriSalus Life Sciences (NASDAQ:TLSI) to Hold

TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Several other research analysts also recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Monday, December 29th. Zacks Research raised TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 16th. Finally, Canaccord Genuity Group upped their target price on TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, TriSalus Life Sciences has a consensus rating of “Hold” and an average price target of $11.00.

TriSalus Life Sciences Price Performance

TLSI opened at $4.97 on Friday. TriSalus Life Sciences has a fifty-two week low of $3.42 and a fifty-two week high of $7.95. The company’s 50 day moving average price is $6.37 and its two-hundred day moving average price is $5.25. The firm has a market capitalization of $248.30 million, a price-to-earnings ratio of -2.46 and a beta of 0.43.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.79). The firm had revenue of $11.57 million for the quarter, compared to analysts’ expectations of $11.76 million. As a group, equities research analysts predict that TriSalus Life Sciences will post -1.55 EPS for the current year.

Institutional Trading of TriSalus Life Sciences

Large investors have recently modified their holdings of the stock. Nantahala Capital Management LLC bought a new position in shares of TriSalus Life Sciences in the second quarter valued at $10,900,000. AWM Investment Company Inc. bought a new position in TriSalus Life Sciences in the 2nd quarter valued at about $6,812,000. Vanguard Group Inc. boosted its stake in TriSalus Life Sciences by 42.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after purchasing an additional 345,186 shares during the last quarter. Gilder Gagnon Howe & Co. LLC increased its holdings in TriSalus Life Sciences by 32.1% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock worth $5,957,000 after purchasing an additional 265,618 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of TriSalus Life Sciences by 107.4% in the second quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after purchasing an additional 235,627 shares during the last quarter. Institutional investors and hedge funds own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.